hrp0089p3-p407 | Diabetes & Insulin P3 | ESPE2018

Degludec Versus Glargine in Pediatric and Adolescent Patients with Type 1 Diabetes

Gil-Poch Estela , Javier Arroyo-Diez Francisco , Beato-Vibora Pilar I

Introduction: To optimal glycemic control without hypoglycemia must be the aim of insulin treatment for all patients with type 1 diabetes (T1DM). Despite the advantages of the basal-bolus insulin regimens with MDI, hypoglycemia presents a major barrier in achieving desirable blood glucose levels. Degludec is a new basal insulin analog with longer half-life and lower variability.Objetive: To investigate the differences between long-acting insulins glargin...

hrp0094p2-362 | Pituitary, neuroendocrinology and puberty | ESPE2021

Congenital hypopituitarism: the role of genetics

Gil Poch Estela , Javier Arroyo Diez Francisco , Mendez Perez Pilar , Galan Gomez Enrique ,

Hypopituitarism refers to the insufficient secretion of one or more pituitary hormones. If default is present at the time of birth is called congenital hypopituitarism (CH). Causes of this are perinatal pathology and genetic alterations. The clinical presentation is heterogeneous. The diagnosis is made by clinical suspicion supported by hormonal determinations, brain imaging test (MRI) searching of structural defects and genetic study. The development of the pituitary gland is...